IMMY appoints infectious disease leader Dr. Tom Chiller as Chief Medical Officer and VP of Strategic Innovation
IMMY announced the appointment of Dr. Tom Chiller, MD, MPHTM, as Chief Medical Officer (CMO) and Vice President of Strategic Innovation. Dr. Chiller, a globally recognized leader in fungal diseases, brings decades of experience in public health, patient-care improvements, and global disease surveillance to IMMY.
Dr. Chiller most recently served as Chief of the Mycotic Diseases Branch at the Centers for Disease Control and Prevention (CDC), where he led national and international efforts to detect, prevent, and respond to fungal infections. Under his leadership, the CDC’s fungal disease program expanded dramatically, growing federal investment from $2 million to over $24 million and launching groundbreaking initiatives such as FungiSurv, the first national surveillance system for fungal diseases. He also played a pivotal role in identifying and responding to emerging threats like Candida auris and advancing global strategies to reduce deaths from cryptococcal infections in HIV.
His work at CDC included spearheading the development of surveillance systems, laboratory capacity, and policy frameworks that have shaped fungal disease response worldwide. Dr. Chiller’s leadership helped secure the inclusion of fungal pathogens in major global health platforms, including the WHO’s Global Antimicrobial Surveillance System and the first-ever WHO fungal priority pathogens list.
At IMMY, Dr. Chiller will serve in a dual leadership role. As CMO, he will ensure that IMMY’s diagnostic innovations are clinically sound, scientifically validated, and aligned with medical standards. As VP of Strategic Innovation, he will drive long-term growth by identifying high-impact strategies, fostering partnerships, and accelerating the development of accessible, life-saving diagnostics.
